top of page
News
Breakthru Medicine Emerges from Stealth with $60M Series A for Cancer Drug Development
Phoenix, AZ, January 29, 2026 (Globe Newswire) Breakthru Medicine emerges from stealth mode with the close of a $60M Series A financing round following a prior undisclosed seed round. Breakthru was founded by biotech industry veterans Steve Potts, PhD, Mark Mulvihill, PhD, and Brian Barnett, MD, to deliver disruptive therapeutic modalities to cancer patients to address major unmet medical needs. Steve Potts has been involved in both the companion diagnostic and cancer drug de
1 day ago
bottom of page